KMT2A and leukemia: Inhibiting key players in the HBP or blocking O-GlcNAc transferase activity was demonstrated to increase cellular sensitivity to DOT1L inhibition, suggesting that targeting DOT1L degradation is a potential therapeutic strategy for MLL-fusion leukemia.